• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Xvivo Perfusion

277.60 SEK

-1.21 %

Less than 1K followers

XVIVO

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.21 %
+1.31 %
+51.20 %
+48.77 %
+55.17 %
-12.15 %
-4.28 %
-15.75 %
+1,361.05 %

Xvivo Perfusion operates in the medical technology industry and focuses on the development and manufacturing of systems for organ transplantation and perfusion. Examples of products that the company supplies include cannulas, organ storage and cooling solutions. The company's products are aimed at healthcare institutions and surgeons. Xvivo Perfusion operates globally, was founded in 1998 and is headquartered in Gothenburg, Sweden.

Read more
Market cap
8.74B SEK
Turnover
10.11M SEK
Revenue
812.17M
EBIT %
10.88 %
P/E
347
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.7
2026

Interim report Q2'26

22.10
2026

Interim report Q3'26

28.1
2027

Annual report '26

Press release5/18/2026, 11:45 AM

Regulatory derogation and reimbursement in France enable life-saving use of XVIVO’s heart technology

Xvivo Perfusion
Press release4/27/2026, 4:22 PM

Redeye: Xvivo Perfusion (Q1 Review): A strong start to an eventful year

Xvivo Perfusion
Regulatory press release4/27/2026, 1:17 PM

Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)

Xvivo Perfusion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Xvivo, Audiocast, Q1'26
Webcast4/24/2026, 12:00 PM

Xvivo, Audiocast, Q1'26

Xvivo Perfusion
Regulatory press release4/24/2026, 5:30 AM

Interim Report January – March 2026

Xvivo Perfusion
Press release4/22/2026, 7:50 PM

XVIVO presents encouraging results from first clinical trial using hypothermic oxygenated perfusion (HOPE) in direct procurement DCD heart transplantation

Xvivo Perfusion
Regulatory press release4/22/2026, 7:24 PM

Preliminary one-year follow-up data from the US PRESERVE trial for XVIVO’s heart technology presented at ISHLT in Toronto

Xvivo Perfusion
Press release4/21/2026, 12:30 PM

Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q1 2026

Xvivo Perfusion
Press release4/17/2026, 11:45 AM

Conference call on Interim Report January-March 2026

Xvivo Perfusion
Press release4/16/2026, 12:00 PM

The 12-month follow-up results from XVIVO’s European multicenter heart trial is now published in the European Heart Journal

Xvivo Perfusion
Regulatory press release4/1/2026, 11:00 AM

Annual report 2025

Xvivo Perfusion
Regulatory press release3/19/2026, 11:30 AM

NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN XVIVO PERFUSION AB (PUBL)

Xvivo Perfusion
Regulatory press release2/20/2026, 1:24 PM

Correction: The Nomination Committee’s proposal for new board members

Xvivo Perfusion
Regulatory press release2/20/2026, 1:00 PM

The Nomination Committee of XVIVO Perfusion AB (publ) proposes Emil Billbäck and Anne-Karen Hunt as new members of the Board of Directors

Xvivo Perfusion
Regulatory press release2/19/2026, 3:45 PM

Management change at XVIVO – CFO transitions to new role

Xvivo Perfusion
Press release2/10/2026, 2:00 PM

Change of date for publication of the Interim report January-March 2026

Xvivo Perfusion
Press release1/28/2026, 10:06 AM

Redeye: XVIVO (Q4 interview) - Redeye talks with CEO Christoffer Rosenblad

Xvivo Perfusion
Press release1/28/2026, 9:03 AM

Redeye: Xvivo Perfusion (Q4 Review) - Setting up for a strong 2026

Xvivo Perfusion
Xvivo, Audiocast, Q4'25
Webcast1/27/2026, 1:00 PM

Xvivo, Audiocast, Q4'25

Xvivo Perfusion
Regulatory press release1/27/2026, 6:30 AM

Year-End Report 2025

Xvivo Perfusion